PCM
ATNM icon

Prelude Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Prelude Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-18,145
Closed -$404K – 1767
2018
Q3 		$404K Buy
+18,145
New +$369K 0.02% 584

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Prelude Capital Management's ATNM Position: Q4 2018 in Review

Prelude Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q4 2018, closing a stake of 18,145 shares — an estimated $404K sold.

Prelude Capital Management first reported a position in ATNM in Q3 2018 and held it in 1 quarter. The position peaked at $404K in Q3 2018. 43 funds tracked by Wall St. Rank hold ATNM as of Q4 2018.

  • Prelude Capital Management reported no remaining Actinium Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Prelude Capital Management sold 18,145 Actinium Pharmaceuticals shares in Q4 2018, an estimated $404K.
  • Prelude Capital Management first reported a position in Actinium Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Prelude Capital Management's Actinium Pharmaceuticals position peaked at $404K in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.